Clinical evidence dossier

DSMES

HbA1c

Evidence signal

Evidence signal

Strong

This is an authoritative evidence signal supplied by Clinical Reference. It is not a formal clinical grade, treatment recommendation, or pooled effect estimate.

Evidence snapshot

Authoritative support records
11
Supporting studies available for review
11
Randomized trials
11
Reported effects
14

Clinical conclusion

DSMES shows a moderate positive evidence signal for improving HbA1c across the studied comparisons.

The conclusion and evidence-signal classification are distinct authoritative fields and are reproduced as published.

Observed effects

Observed study estimates; not a pooled treatment effect.

Change from baseline

Absolute change

−0.84% to −0.76%

4 eligible estimates12–16 weeksObserved median: −0.81%

Change from baseline

Mean difference

−0.77% to −0.2%

6 eligible estimates12–52 weeksObserved median: −0.6%

Between-group effect

Mean difference

−0.1% to −0.1%

1 eligible estimates52–52 weeksObserved median: −0.1%

Change from baseline

Mean difference

−0.84 mmol/mol to −0.84 mmol/mol

2 eligible estimates52–52 weeksObserved median: −0.84 mmol/mol

Evidence composition

Non-randomized studies
0
Other designs
0
Unresolved designs
0
Magnitude-eligible effects
13

Consistency

Consistency classification

Mostly consistent

Positive
7
No effect
3
Mixed
0
Negative
1

Population and applicability

Structured population data were available for 11 of 11 supporting studies. Diabetes type was heterogeneous: 8 studies with type 2 diabetes, 1 studies with type 1 diabetes. Age groups were heterogeneous: 9 studies with adult participants, 1 studies with youth participants.

This population information refers to the materialized supporting studies available for review. Omitted support records remain part of the authoritative support accounting and are available through the audit experience.

View reported population descriptions

These descriptions are reported across the supporting studies; they are not a single synthesized population.

  • Latino adults aged 18 and older with uncontrolled type 2 diabetes.
  • Individuals seeking culturally relevant diabetes education and support.
  • Adults aged 18 and older with type 2 diabetes.
  • Individuals seeking improved diabetes self-management strategies.
  • Adults with diabetes seeking improved management strategies.
  • Patients interested in digital health solutions for chronic conditions.
  • Individuals with diabetes seeking better management strategies.
  • Families of patients with diabetes involved in care.
  • Adults with type 2 diabetes
  • Adults with prediabetes
  • Rural populations
  • Adults diagnosed with type 2 diabetes.

Limitations

  • 2 supporting studies do not have a displayable topic-matched quantitative effect.
  • Evidence uses heterogeneous comparison contexts: active_comparator, baseline_within_group, unknown_unresolved, usual_care.

Supporting evidence

Inspect the authoritative studies and omitted support records for this dossier.

View supporting evidence